Mitsubishi Tanabe ups profit forecast on lower costs
This article was originally published in Scrip
Lower than expected costs in the first half have led Japan's Mitsubishi Tanabe Pharma (MTP) to raise its consolidated net profit guidance for the first half ended September 30th by ¥3.5 billion to ¥13.5 billion ($149.5 million).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.